EUVIMEDEUVIMED entdecken
Open Access

Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors

Fangzheng Yuan iD, Carrie Lenneman, Ronald Krone iD, Grant R Williams iD, Darryl Outlaw iD, Michael Katsnelson iD, Stephen Lirette iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.2896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Fangzheng Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Alabama at Birmingham Hospital, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cardiovascular Diseases, Phenylurea Compounds. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vascular endothelial growth factor inhibitors, including tyrosine kinase inhibitors (TKIs) and anti‐angiogenics, are first‐line therapies for advanced and metastatic hepatocellular carcinoma. Although TKIs have a greater potential for off‐target adverse effects compared with bevacizumab (anti‐angiogenics), a direct comparison of the risk of cardiovascular adverse events between these two types of therapies has not been performed.

Objective

To compare the incidence of and characterize cardiovascular adverse events in patients with hepatocellular carcinoma receiving TKIs versus bevacizumab.

Methods

This cohort study included adult patients with hepatocellular carcinoma who received first‐line TKIs (sorafenib or lenvatinib) or bevacizumab at two academic medical centers and one community cancer center from September 2018 to August 2021. The primary outcome was risk of cardiovascular adverse events. Major secondary outcomes included the incidence of individual types of cardiovascular adverse events and risk factors associated with major adverse cardiovascular events (MACE).

Results

The study included 221 patients (159 TKI patients; 62 bevacizumab patients). At a median follow‐up of 5 months, the probability of cardiovascular adverse events was not significantly different between the two groups (hazard ratio [HR]: 0.85; 95% confidence interval [95% CI]: 0.58–1.24; p = 0.390). The cumulative incidence of cardiovascular events was highest in patients receiving lenvatinib (sub‐distribution hazard ratio [SHR]: 1.53; 95% CI: 1.02–2.30) compared with those receiving sorafenib (reference) or bevacizumab (SHR: 1.05; 95% CI: 0.68–1.64) after adjustment for comorbidities, liver transplant status, and presence of portal vein thrombosis at baseline. Cardiovascular adverse events were observed in 151 (68%) patients, and MACE were observed in 27 (12%) patients. Risk factors associated with MACE were hypertension (SHR: 3.5; 95% CI: 0.9087–15.83; p = 0.086), prior history of MACE (SHR: 2.01; 95% CI: 0.83–4.87; p = 0.124), and tobacco use (SHR: 2.85; 95% CI: 0.90–8.97; p = 0.074).

Conclusions

Cardiovascular risk was not significantly different between TKIs and bevacizumab. Lenvatinib appears to have the highest risk of cardiovascular adverse events among these first‐line VEGF inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsCardiovascular DiseasesPhenylurea CompoundsQuinolinesAdultHumansBevacizumabVascular Endothelial Growth Factor ASorafenibCohort Studies

Stichwörter der Autor:innen

bevacizumabhepatocellular cancersorafenibtyrosine kinase inhibitor

Substanzen

BevacizumablenvatinibVascular Endothelial Growth Factor ASorafenibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Pharmacy, University of Alabama at Birmingham Hospital, Birmingham, Alabama, USA.
  • Department of Research, Baptist Hospitals of Southeast Texas, Beaumont, Texas, USA.
  • Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
  • Division of Cardiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.

ORCID-Profile: Fangzheng Yuan, Ronald Krone, Grant R Williams, Darryl Outlaw, Michael Katsnelson, Stephen Lirette

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Yuan, F., Lenneman, C., Krone, R., Williams, G. R., Outlaw, D., Katsnelson, M., & Lirette, S. (2024). Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2896

Vancouver

Yuan F, Lenneman C, Krone R, Williams GR, Outlaw D, Katsnelson M, et al. Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.2896

BibTeX
@article{Yuan2024,
  author = {Yuan, Fangzheng and Lenneman, Carrie and Krone, Ronald and Williams, Grant R and Outlaw, Darryl and Katsnelson, Michael and Lirette, Stephen},
  title = {Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.2896}
}
Kostenlos starten →